Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : TopoTarget A/S
Femme et Homme Max 99 ans
TopoTarget A/S
MAJ Il y a 5 ans
A double-blind, randomised, parallel group, placebo-controlled dose finding Phase II study to compare the efficacy and safety of topically applied Avugane™ of different concentrations in subjects with mild to moderate acne vulgaris
The primary objective of the study is to compare the efficacy of different concentrations of the study treatment Avugane™ on facial papulopustular acne in comparison to a placebo control.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
TopoTarget A/S
MAJ Il y a 5 ans
A multi-centre, two-stage, open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with advanced melanoma
The primary objective of this clinical trial is to determine the anti-tumor activity of APO866 in patients with advanced cutaneous melanoma.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
TopoTarget A/S
MAJ Il y a 5 ans
APO866 for B-Cell Leukaemia. An open phase I/II clinical study assessing the safety and tolerability of APO866 in patients with refractory B-cell lymphocytic leukaemia not amenable to allogeneic hemopoietic stem cell transplantation
The main objectives of this study are: 1. To asses the safety and the tolerability of 1 cycle of APO866, administered by continuous intravenous infusion, in patients with refractory B-cell chronic ly...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
TopoTarget A/S
MAJ Il y a 5 ans
A Phase I/II Clinical Trial of PXD101 in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy
The primary objective of this trial for the two schedules of PXD101 and idarubicin combination treatment is to determine the safety and tolerance (Maximum Tolerated Dose, Dose Limiting Toxicity) and ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme
Entre 18 ans
et 99 ans
TopoTarget A/S
MAJ Il y a 5 ans
TOPOTARGET PXD101-CLN-17 : Essai de phase 2 randomisé comparant un traitement associant le carboplatine et le paclitaxel, avec ou sans belinostat, chez des patients ayant un cancer de primitif inconnu non préalablement traité. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carc...
Pays
France
Organes
Cancer de primitif inconnu (CAPI)
Spécialités
Chimiothérapie
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
TopoTarget A/S
MAJ Il y a 5 ans
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients with Advanced Solid Tumours
Following establishment of MTD up to a total of 32 patients with epithelial ovarian, primary peritoneal, fallopian tube or mixed mullerian tumours of ovarian origin may be enrolled at the MTD dose lev...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2